Updating results

464 results

Sort: Relevance | Date

Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404

In development [GID-TA10327] Expected publication date: TBC

Technology appraisal guidance In development

Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

In development [GID-TA10222] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

In development [GID-TA10415] Expected publication date: TBC

Technology appraisal guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

NICE guideline In development

Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

NICE guideline In development

Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

NICE guideline In development

Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

NICE guideline In development

Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

NICE guideline In development

Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

NICE guideline In development

Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

NICE guideline In development

Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

NICE guideline In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Technology appraisal guidance In development

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

In development [GID-TA10452] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

In development [GID-TA10502] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

In development [GID-TA10546] Expected publication date: TBC

Technology appraisal guidance In development

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

In development [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

In development [GID-TA10480] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Technology appraisal guidance In development

Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]

In development [GID-TA10224] Expected publication date: TBC

Technology appraisal guidance In development

Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Technology appraisal guidance In development

Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Technology appraisal guidance In development

NBTXR-3 for treating soft tissue sarcoma [ID1050]

In development [GID-TA10226] Expected publication date: TBC

Technology appraisal guidance In development

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Technology appraisal guidance In development

LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

In development [GID-TA10211] Expected publication date: TBC

Technology appraisal guidance In development

Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development